Analytical Data
-
Gene name
VACWR170
- Application
-
Alternative Names
(3-beta-HSD)(5)(3-beta-hydroxy-5-ene steroid dehydrogenase)(Progesterone reductase)(Delta-5-3-ketosteroid isomerase)
-
Species
Vaccinia virus
-
Source
E. coli
-
Tag
N- His & C- Myc
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P26670
-
Expression Region
1-346aa
-
Molecular Weight
46.9 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
The VACWR170 protein, derived from Vaccinia virus, has garnered significant interest in the field of virology and immunology due to its potential applications in vaccine development and cancer immunotherapy. As a member of the viral protein family, VACWR170 plays a key role in the virus's ability to evade host immune responses, making it a target for research aimed at understanding viral pathogenesis. Studies have shown that VACWR170 can modulate immune signaling pathways, thereby influencing T-cell activation and cytokine production. This unique function presents an opportunity to manipulate the protein for therapeutic purposes, such as enhancing immune responses against tumors or infectious agents. Additionally, VACWR170's interaction with various host cell proteins has provided insights into fundamental mechanisms of immune evasion, which could lead to the design of novel vaccines that leverage these pathways to improve their efficacy. Ongoing research aims to elucidate the structural and functional properties of VACWR170, paving the way for its utilization in innovative immunotherapeutic strategies. By harnessing the mechanisms employed by VACWR170, scientists hope to develop more effective approaches to combat cancer and infectious diseases, ultimately contributing to advancements in public health and therapeutic interventions.
